Skip to main content
Top
Published in: Medical Microbiology and Immunology 6/2017

01-12-2017 | Original Investigation

The impact of KIR–HLA genotype on hepatitis B virus clearance in Iranian infected individuals

Authors: Alireza Shah-Hosseini, Mohammad Jafari, Asadollah Mohammadi, Roozbeh Sanaei, Seyed Moayed Alavian, Amin Doosti-Irani, Mehrnoush Nooradeh Keykavousi, Nader Tajik

Published in: Medical Microbiology and Immunology | Issue 6/2017

Login to get access

Abstract

Killer cell immunoglobulin like receptors (KIRs) have a principal role in regulating the effector functions of NK cells, particularly in viral infections. The major ligands for KIRs are human leukocyte antigen (HLA) class I molecules. The aim of this study is to investigate the possible association of KIR genes, their known HLA ligands and compound KIR–HLA genotypes with hepatitis B virus (HBV) infection. Our study group consisted of 202 Iranian HBV-infected patients (52 spontaneously recovered, 50 asymptomatic carriers, 50 chronic sufferers and 50with liver cirrhosis) and 100 ethnic-matched healthy control subjects. KIR and HLA genotyping was performed by a polymerase chain reaction–sequence-specific primer (PCR–SSP). The frequencies of the KIR2DL5A, KIR2DS1, and KIR3DS1 genes were significantly elevated in recovered individuals when compared with both control and patient groups. Also, KIR2DL5, and KIR3DP1 full were escalated in recovered individuals in comparison with patient groups. In addition, HLA-Bw4 ligand and HLA-A Bw4 were highly frequent in recovered individuals compared with healthy controls. Furthermore, the KIR3DS1 + HLA-Bw4, KIR3DS1 + HLA-Bw4 Iso80 , and KIR3DS1 + HLA-A Bw4 genotypes were significantly more common in recovered individuals than both healthy control and patient groups. Interestingly, AA genotype had less frequency and Bx had higher frequency in recovered individuals compared with both healthy control and patient groups. Our findings suggest a potential impact of the NK cells’ activating phenotype that leads to the HBV clearance in infected individuals.
Literature
2.
go back to reference Chen Y et al (2005) Activation and function of hepatic NK cells in hepatitis B infection: an underinvestigated innate immune response. J Viral Hepat 12:38–45CrossRefPubMed Chen Y et al (2005) Activation and function of hepatic NK cells in hepatitis B infection: an underinvestigated innate immune response. J Viral Hepat 12:38–45CrossRefPubMed
3.
go back to reference Webster GJ et al (2004) Longitudinal analysis of CD8 + T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 78:5707–5719CrossRefPubMedPubMedCentral Webster GJ et al (2004) Longitudinal analysis of CD8 + T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 78:5707–5719CrossRefPubMedPubMedCentral
4.
go back to reference Li W et al (2011) Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population. Liver Int 31:1118–1126CrossRefPubMed Li W et al (2011) Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population. Liver Int 31:1118–1126CrossRefPubMed
5.
go back to reference Zhang Z et al (2011) Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients. Hepatology 53:73–85CrossRefPubMed Zhang Z et al (2011) Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients. Hepatology 53:73–85CrossRefPubMed
6.
go back to reference Zhang E, Lu M (2015) Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection. Med Microbiol Immunol 204(1):11–20CrossRefPubMed Zhang E, Lu M (2015) Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection. Med Microbiol Immunol 204(1):11–20CrossRefPubMed
7.
go back to reference Fisicaro P et al (2009) Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 58:974–982CrossRefPubMed Fisicaro P et al (2009) Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 58:974–982CrossRefPubMed
8.
go back to reference Jamil KM, Khakoo SI (2011) KIR/HLA interactions and pathogen immunity. Biomed Res Int 2011:298348 Jamil KM, Khakoo SI (2011) KIR/HLA interactions and pathogen immunity. Biomed Res Int 2011:298348
9.
go back to reference Solgi G et al (2011) Comparison of KIR gene content profiles revealed a difference between northern and southern Persians in the distribution of KIR2DS5 and its linked loci. Hum Immunol 72:1079–1083CrossRefPubMed Solgi G et al (2011) Comparison of KIR gene content profiles revealed a difference between northern and southern Persians in the distribution of KIR2DS5 and its linked loci. Hum Immunol 72:1079–1083CrossRefPubMed
10.
go back to reference Tjwa ET et al (2011) Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B. J Hepatol 54:209–218CrossRefPubMed Tjwa ET et al (2011) Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B. J Hepatol 54:209–218CrossRefPubMed
11.
12.
go back to reference Campbell KS, Purdy AK (2011) Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology 132:315–325CrossRefPubMedPubMedCentral Campbell KS, Purdy AK (2011) Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology 132:315–325CrossRefPubMedPubMedCentral
13.
go back to reference Steffens U et al (1998) Nucleotide and amino acid sequence alignment for human killer cell inhibitory receptors (KIR), 1998. Tissue Antigens 51:398–413CrossRefPubMed Steffens U et al (1998) Nucleotide and amino acid sequence alignment for human killer cell inhibitory receptors (KIR), 1998. Tissue Antigens 51:398–413CrossRefPubMed
15.
go back to reference Trowsdale J (2001) Genetic and functional relationships between MHC and NK receptor genes. Immunity 15:363–374CrossRefPubMed Trowsdale J (2001) Genetic and functional relationships between MHC and NK receptor genes. Immunity 15:363–374CrossRefPubMed
16.
go back to reference Uhrberg M et al (1997) Human diversity in killer cell inhibitory receptor genes. Immunity 7:753–763CrossRefPubMed Uhrberg M et al (1997) Human diversity in killer cell inhibitory receptor genes. Immunity 7:753–763CrossRefPubMed
17.
go back to reference Vilches C, Parham P (2002) KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol 20:217–251CrossRefPubMed Vilches C, Parham P (2002) KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol 20:217–251CrossRefPubMed
19.
go back to reference Gumperz JE et al (1995) The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med 181:1133–1144CrossRefPubMed Gumperz JE et al (1995) The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med 181:1133–1144CrossRefPubMed
20.
go back to reference Thananchai H et al (2007) Cutting Edge: Allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B. J Immunol 178:33–37CrossRefPubMed Thananchai H et al (2007) Cutting Edge: Allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B. J Immunol 178:33–37CrossRefPubMed
21.
go back to reference Pende D et al (1996) The natural killer cell receptor specific for HLA-A allotypes: a novel member of the p58/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140-kD disulphide-linked dimer. J Exp Med 184:505–518CrossRefPubMed Pende D et al (1996) The natural killer cell receptor specific for HLA-A allotypes: a novel member of the p58/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140-kD disulphide-linked dimer. J Exp Med 184:505–518CrossRefPubMed
22.
go back to reference Döhring C et al (1996) A human killer inhibitory receptor specific for HLA-A1, 2. J Immunol 156(9):3098–3101PubMed Döhring C et al (1996) A human killer inhibitory receptor specific for HLA-A1, 2. J Immunol 156(9):3098–3101PubMed
23.
go back to reference Carr WH, Pando MJ, Parham P (2005) KIR3DL1 polymorphisms that affect NK cell inhibition by HLA-Bw4 ligand. J Immunol 175:5222–5229CrossRefPubMed Carr WH, Pando MJ, Parham P (2005) KIR3DL1 polymorphisms that affect NK cell inhibition by HLA-Bw4 ligand. J Immunol 175:5222–5229CrossRefPubMed
24.
go back to reference Sivori S et al (2011) Natural killer cells expressing the KIR2DS1-activating receptor efficiently kill T-cell blasts and dendritic cells: implications in haploidentical HSCT. Blood 117:4284–4292CrossRefPubMed Sivori S et al (2011) Natural killer cells expressing the KIR2DS1-activating receptor efficiently kill T-cell blasts and dendritic cells: implications in haploidentical HSCT. Blood 117:4284–4292CrossRefPubMed
25.
go back to reference Chewning JH et al (2007) KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro. J Immunol 179:854–868CrossRefPubMed Chewning JH et al (2007) KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro. J Immunol 179:854–868CrossRefPubMed
26.
go back to reference Stewart CA et al (2005) Recognition of peptide–MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci USA 102:13224–13229CrossRefPubMedPubMedCentral Stewart CA et al (2005) Recognition of peptide–MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci USA 102:13224–13229CrossRefPubMedPubMedCentral
27.
28.
go back to reference Tajik N et al (2009) Distribution of KIR genes in the Iranian population. Tissue Antigens 74:22–31CrossRefPubMed Tajik N et al (2009) Distribution of KIR genes in the Iranian population. Tissue Antigens 74:22–31CrossRefPubMed
29.
go back to reference Tajik N et al (2010) Compound KIR–HLA genotype analyses in the Iranian population by a novel PCR–SSP assay. Int J Immunogenet 37:159–168CrossRefPubMed Tajik N et al (2010) Compound KIR–HLA genotype analyses in the Iranian population by a novel PCR–SSP assay. Int J Immunogenet 37:159–168CrossRefPubMed
30.
go back to reference McQueen KL et al (2007) Donor–recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation. Hum Immunol 68:309–323CrossRefPubMedPubMedCentral McQueen KL et al (2007) Donor–recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation. Hum Immunol 68:309–323CrossRefPubMedPubMedCentral
31.
go back to reference Singh R et al (2007) A comparative review of HLA associations with hepatitis B and C viral infections across global populations. World J Gastroenterol 13:1770CrossRefPubMedPubMedCentral Singh R et al (2007) A comparative review of HLA associations with hepatitis B and C viral infections across global populations. World J Gastroenterol 13:1770CrossRefPubMedPubMedCentral
32.
go back to reference Moretta A et al (1995) Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells. J Exp Med 182:875–884CrossRefPubMed Moretta A et al (1995) Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells. J Exp Med 182:875–884CrossRefPubMed
33.
go back to reference Kalyanaraman N, Thayumanavan L, Jayalakshmi M (2016) KIR: HLA association with clinical manifestations of HBV infection in Madurai, south India. J Genet 95:13–19CrossRefPubMed Kalyanaraman N, Thayumanavan L, Jayalakshmi M (2016) KIR: HLA association with clinical manifestations of HBV infection in Madurai, south India. J Genet 95:13–19CrossRefPubMed
34.
go back to reference Zhi-ming L et al (2007) Polymorphisms of killer cell immunoglobulin-like receptor gene: possible association with susceptibility to or clearance of hepatitis B virus infection in Chinese Han population. Croat Med J 48:800CrossRefPubMedPubMedCentral Zhi-ming L et al (2007) Polymorphisms of killer cell immunoglobulin-like receptor gene: possible association with susceptibility to or clearance of hepatitis B virus infection in Chinese Han population. Croat Med J 48:800CrossRefPubMedPubMedCentral
35.
go back to reference Di Bona D et al (2017) KIR2DL3 and the KIR ligand groups HLA‐A‐Bw4 and HLA‐C2 predict the outcome of hepatitis B virus infection. J Viral Hepat 24(9):768–775CrossRefPubMed Di Bona D et al (2017) KIR2DL3 and the KIR ligand groups HLA‐A‐Bw4 and HLA‐C2 predict the outcome of hepatitis B virus infection. J Viral Hepat 24(9):768–775CrossRefPubMed
36.
go back to reference Khakoo SI et al (2004) HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305:872–874CrossRefPubMed Khakoo SI et al (2004) HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305:872–874CrossRefPubMed
37.
go back to reference Knapp S et al (2010) Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus. Hepatology 51:1168–1175CrossRefPubMedPubMedCentral Knapp S et al (2010) Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus. Hepatology 51:1168–1175CrossRefPubMedPubMedCentral
38.
go back to reference Kibar F et al (2014) Role of KIR genes and genotypes in susceptibility to or protection against hepatitis B virus infection in a Turkish cohort. Med Sci Monit 20:28CrossRefPubMedPubMedCentral Kibar F et al (2014) Role of KIR genes and genotypes in susceptibility to or protection against hepatitis B virus infection in a Turkish cohort. Med Sci Monit 20:28CrossRefPubMedPubMedCentral
39.
go back to reference Martin MP et al (2002) Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 31:429–434PubMed Martin MP et al (2002) Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 31:429–434PubMed
40.
go back to reference Bonagura VR et al (2010) Activating killer cell immunoglobulin-like receptors 3DS1 and 2DS1 protect against developing the severe form of recurrent respiratory papillomatosis. Hum Immunol 71:212–219CrossRefPubMed Bonagura VR et al (2010) Activating killer cell immunoglobulin-like receptors 3DS1 and 2DS1 protect against developing the severe form of recurrent respiratory papillomatosis. Hum Immunol 71:212–219CrossRefPubMed
Metadata
Title
The impact of KIR–HLA genotype on hepatitis B virus clearance in Iranian infected individuals
Authors
Alireza Shah-Hosseini
Mohammad Jafari
Asadollah Mohammadi
Roozbeh Sanaei
Seyed Moayed Alavian
Amin Doosti-Irani
Mehrnoush Nooradeh Keykavousi
Nader Tajik
Publication date
01-12-2017
Publisher
Springer Berlin Heidelberg
Published in
Medical Microbiology and Immunology / Issue 6/2017
Print ISSN: 0300-8584
Electronic ISSN: 1432-1831
DOI
https://doi.org/10.1007/s00430-017-0522-1

Other articles of this Issue 6/2017

Medical Microbiology and Immunology 6/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.